Eaton, AMD and SpaceX: CNBC ‘Final Trades’ - Advanced Micro Devices (NASDAQ:AMD)
CNBC's 'Final Trades' featured picks from analysts: Joseph Terranova chose Eaton (ETN), supported by Wells Fargo's Overweight rating and $503 target. Stephanie Link mentioned SpaceX (SPCX), down 26% from highs, after its Starship launch. Jason Snipe picked AbbVie (ABBV) following FDA approval of Juvmo. Joshua Brown recommended AMD (AMD), with StoneX maintaining a Buy rating and $685 target. Shares of ETN, SPCX, ABBV, and AMD showed mixed price action.
How this was made
The 30-second read
Why it matters
The mix of analyst recommendations, regulatory approval, and aerospace achievement provides several short‑term trading angles, though most moves are modest.
Market read
The article offers fresh regulatory and operational news that could influence sector sentiment, especially in biotech and aerospace.
What to watch
AbbVie's drug faces competition and reimbursement risk; SpaceX's commercial viability still hinges on future launch cadence.
Background
The article recaps final trade picks from a CNBC segment, adds a fresh FDA approval, and notes SpaceX's latest orbital flight.
Ticker impact
Eaton was highlighted as a final trade pick on CNBC, with a new Overweight rating and $503 price target.
likely modest upside as the market prices the new Overweight rating
The coverage is fresh but the price target is modest; price already up 0.4%.
SpaceX was noted as still down 26% from highs, but its Starship reached orbit on Flight 14.
potential short‑term rally as investors react to the launch success
Shares rose 2.6% after the news, indicating positive market reaction.
The FDA approved AbbVie’s Juvmo tablets for Parkinson’s disease.
likely modest upside over the next weeks as the drug rolls out
Despite a 1.1% dip on the day, the approval is a material catalyst for future sales.
AMD was recommended by a CNBC guest and a StoneX analyst reiterated a $685 price target.
little immediate move; price already slipped 0.1% on the day
The recommendation repeats prior coverage; no new data was disclosed.
Market effects
Energy and aerospace sectors may see heightened interest after SpaceX's orbital success; biotech gains from AbbVie's new Parkinson's therapy.
U.S. markets receive modest uplift from the FDA approval and analyst coverage.
SpaceX's launch showcases U.S. commercial space capabilities, potentially influencing global aerospace sentiment.
Counterpoint
The modest price moves suggest the market may have already priced in these catalysts; further upside could be limited.
Key entities
- CompanyEaton Corp.
Power management solutions provider.
- CompanySpaceX
Commercial space launch company.
- CompanyAbbVie
Pharmaceutical firm with new Parkinson's drug approval.
- CompanyAdvanced Micro Devices
Semiconductor manufacturer.
